Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services informed exchanges that its subsidiary Optival Health Solutions received three drug license suspension orders from Drug Control Administration authorities in Karnataka and Telangana. The suspensions affect stores at Basavanguli-Rathnavilas road (Karnataka, 3 days), West Marredpally Secundrabad (Telangana, 7 days), and Satyanarayana Colony Shameerpet (Telangana, 3 days). The orders were received on July 14, 2025, under Rule 65 of the Drugs and Cosmetics Act, 1940. Total potential revenue loss across all three stores is approximately Rs 3.88 lakhs, which is negligible relative to the company's overall operations.
The financial impact is minimal at around Rs 3.88 lakhs in potential revenue loss across just three stores out of Medplus's large network. This is a routine regulatory compliance matter with no meaningful effect on shareholders or stock price.